Benefits
Blood Sugar Regulation
In a pooled analysis of 27 randomized trials in 2,569 people with type 2 diabetes, high blood lipids or high blood pressure, berberine tended to lower fasting and after-meal blood glucose and HbA1c compared with placebo or lifestyle changes alone. The authors said the benefit can be substantiated only to a limited degree because the trials were of limited quality. No cited trial measured GLP-1 or appetite.
Cardiovascular Health
In the same 27-trial pooled analysis, and in a pooled analysis of 10 trials in 811 people with fatty liver disease, berberine lowered total cholesterol, LDL cholesterol and triglycerides compared with control, and blood pressure tended to come down in the first analysis. Everyone studied had a diagnosed metabolic or liver condition, and neither review measured heart attacks, strokes or other heart events.
Weight Management
In the pooled analysis of 10 trials in 811 people with fatty liver disease, BMI came down more than with control (standardized mean difference -0.58). No cited study tested berberine as a weight loss product in healthy people or measured appetite, so any weight change here was seen in patients alongside other metabolic changes.
Fewer loose stools and less bowel urgency
In one placebo-controlled trial, 132 people with diarrhea-predominant irritable bowel syndrome took berberine hydrochloride 400 mg a day in two doses for 8 weeks. Diarrhea, abdominal pain and urgent bowel movements became less frequent than with placebo, and berberine was well tolerated. This single trial has not been repeated.
Mechanism of action
AMPK activation (laboratory and animal work)
In cell and animal studies berberine activates AMPK, an enzyme that helps cells switch between burning sugar and fat. A 2025 review names this as a main proposed route for its effects on body fat and blood sugar, but none of the human trials cited here measured AMPK.
Fat cell formation (laboratory and animal work)
The same review describes berberine damping PPAR-gamma, a switch that drives the formation of new fat cells, and raising UCP1, a protein linked to heat-producing fat. These findings come from laboratory and animal models, not from people.
Gut microbiota modulation
Animal and laboratory studies summarized in the review report shifts in gut bacteria with berberine. No study cited on this page measured gut bacteria in people, so this stays a hypothesis rather than a demonstrated effect.
Poor absorption
Less than 1% of an oral berberine dose reaches the bloodstream, according to the review, because the gut pumps it back out and breaks much of it down before it is absorbed. That is one reason doses are large and split through the day.
Slowing of drug-clearing liver enzymes
In healthy men, 2 weeks of berberine at 300 mg three times a day reduced the activity of the liver enzymes CYP2D6, CYP2C9 and CYP3A4, which clear many common medicines. This is why berberine can raise blood levels of other drugs.
Clinical trials
Systematic review and meta-analysis of 27 randomized controlled trials with 2,569 patients, testing berberine alone or alongside lifestyle changes or medicines in type 2 diabetes, high blood lipids and high blood pressure (Lan et al. 2015, J Ethnopharmacol)
2,569 patients across 27 trials, all with diagnosed type 2 diabetes, high blood lipids or high blood pressure.
Berberine with lifestyle changes tended to lower fasting and after-meal blood glucose, HbA1c and blood pressure more than lifestyle changes alone or placebo, and improved total and LDL cholesterol. It did not differ significantly from standard oral diabetes drugs, and no serious adverse reactions were reported. The authors said that, because of the limited quality of the included trials, the benefit can be substantiated only to a limited degree.
Randomized, double-blind, placebo-controlled Phase 2 trial (NCT03656744) of HTD1801, an investigational drug that pairs berberine with the prescription medicine ursodeoxycholic acid; not a berberine supplement (Harrison et al. 2021, Nat Commun)
100 adults with presumed non-alcoholic steatohepatitis and type 2 diabetes, 18 weeks.
At 1,000 mg twice daily for 18 weeks, liver fat fell by 4.8 percentage points versus 2.0 on placebo (p=0.011). Diarrhea and abdominal discomfort were the most common side effects. These results belong to the investigational drug and do not transfer to a berberine supplement.
Randomized, double-blind, placebo-controlled pilot trial; HIMABERB berberine 500 mg three times a day or placebo for 12 weeks (Panigrahi et al. 2023, BMC Endocr Disord)
34 adults with prediabetes, 12 weeks.
Fasting glucose fell from 6.75 to 5.33 mmol/L and HbA1c from 6.40% to 5.43% in the berberine group, and fasting insulin, 2-hour glucose and HOMA-IR also improved compared with placebo. No serious side effects or liver or kidney problems were seen. With 34 people over 12 weeks in a study its authors call a pilot, this is an early signal, not proof.
Systematic review and meta-analysis of 10 randomized controlled trials with 811 patients with non-alcoholic fatty liver disease (Nie et al. 2024, J Transl Med)
811 patients with diagnosed non-alcoholic fatty liver disease across 10 trials.
Berberine improved ALT, AST and GGT, triglycerides, total and LDL cholesterol, HOMA-IR and BMI compared with control, with only mild digestive side effects reported. HDL cholesterol did not change significantly. The authors see berberine as a possible add-on for fatty liver disease, which is a decision for the doctor managing that diagnosis.
Phase 2, randomized, double-blind, placebo-controlled trial in 113 Chinese adults with type 2 diabetes (38 placebo, 37 on 500 mg twice daily, 38 on 1,000 mg twice daily) of berberine ursodeoxycholate, an investigational drug, not a supplement (Ji et al. 2025, JAMA Netw Open)
113 Chinese adults with type 2 diabetes, 12 weeks.
HbA1c fell by 0.4 percentage points on 500 mg and by 0.7 on 1,000 mg twice daily compared with placebo over 12 weeks. The trial never compared this drug with ordinary berberine, so it says nothing about how a berberine supplement would perform.
Randomized, double-blind, placebo-controlled trial; berberine 900 mg a day or placebo added to antipsychotic medication for 8 weeks; 65 enrolled and 49 finished (Li et al. 2021, Psychiatry Res)
65 people with schizophrenia on antipsychotic medication, 49 of whom completed the 8 week study.
Total cholesterol, LDL cholesterol, fasting insulin and insulin resistance improved compared with placebo. This study is about blunting the metabolic side effects of antipsychotic medication in people with a serious mental illness under specialist care. It says nothing about what berberine does for a healthy person, and anyone taking antipsychotics should only consider berberine with their psychiatrist, since it can also change blood levels of other medicines.
Randomized, double-blind, placebo-controlled trial; berberine hydrochloride 400 mg a day in two doses or placebo for 8 weeks, then a 4-week washout (Chen et al. 2015, Phytother Res)
132 people with diarrhea-predominant irritable bowel syndrome, out of 196 recruited
Diarrhea frequency (P = 0.032), abdominal pain frequency and urgency (both P < 0.01) fell more than with placebo, symptom, mood and quality of life scores trended better, and berberine was well tolerated. A single trial that has not been repeated.